Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 58.2%

Neg 0% Neu 58.2% Pos 0%

Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.